Ten nephroblastomas were investigated by antibodies to intermediate filaments. In seven cases, which in light microscopy were characterized by the presence of blastema and tubules, immunofluorescence microscopy with IF-specific antibodies reveals expression of cytokeratin and vimentin in blastema cells, while tubules were only labelled by the cytokeratin antibodies. This result was independent of whether the conventional cytokeratin antibody or monoclonal antibodies specific for cytokeratin 18 were used. Stroma cells were vimentin-positive. In two cases nephroblastomas were undifferentiated and also lacked tubuli formation. In both these tumors blastema cells were vimentin-positive and cytokeratin-negative. Finally one case of clear cell sarcoma of the kidney could only be labelled by the vimentin antibody. Thus antibodies to intermediate filaments seem to be useful tools to distinguish nephroblastomas from neuroblastomas or rhabdomyosarcomas, especially in cases of metastasis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/BF02889858 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
CryoEM structure of an MHC-I/TAPBPR peptide-bound intermediate reveals the mechanism of antigen proofreading.
Proc Natl Acad Sci U S A
January 2025
Department of Biochemistry and Biophysics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104.
Class I major histocompatibility complex (MHC-I) proteins play a pivotal role in adaptive immunity by displaying epitopic peptides to CD8+ T cells. The chaperones tapasin and TAPBPR promote the selection of immunogenic antigens from a large pool of intracellular peptides. Interactions of chaperoned MHC-I molecules with incoming peptides are transient in nature, and as a result, the precise antigen proofreading mechanism remains elusive.
View Article and Find Full Text PDFApplication of blood biomarkers for the future anti‐Aβ antibody therapy in Japan.
Alzheimers Dement
December 2024
Brain Research Institute, Niigata University, Niigata, Niigata, Japan
Background: With the approval of Lecanemab in Japan following the U.S., biomarker‐based diagnosis of AD will be required in daily practice.
View Article and Find Full Text PDFAlpha‐internexin is detectable in cerebrospinal fluid – an analogue to neurofilament light?
Alzheimers Dement
December 2024
Hong Kong Center for Neurodegenerative Diseases, Hong Kong, China
Background: Alpha‐internexin (AINX) is a type IV intermediate filament alongside the neurofilament triplet proteins. Although AINX is mostly expressed during the development of the brain, it is still present in mature neurons and reported to be involved in axonal outgrowth. Because of a lack of previously published studies quantifying AINX in cerebrospinal fluid (CSF), and its high sequence similarity with other neurofilaments, the objective of this project was to specifically detect AINX via antibody‐based techniques and assess its biomarker capabilities.
View Article and Find Full Text PDFUse of a blood‐based amyloid test for screening in INVOKE‐2: a phase 2 randomized, double‐blind, placebo‐controlled study evaluating AL002 in early Alzheimer’s disease.
Alzheimers Dement
December 2024
Alector, South San Francisco, CA, USA
Background: The PrecivityAD® blood‐test (C2N Diagnostics) predicts cerebral amyloidosis due to Alzheimer’s Disease (AD). PrecivityAD® incorporates plasma Aβ42/40, age and apoE proteotype into an algorithm that generates an amyloid probability score (APS) corresponding to the likelihood of a positive amyloid PET scan, defined as ≥25 centiloid (CL). A prototype PrecivityAD algorithm validated against amyloid PET status scored by visual read (VR) was used to improve screening efficiency in INVOKE‐2, a phase 2 randomized, double‐blind, placebo‐controlled trial evaluating TREM2‐activating antibody AL002 in early AD.
View Article and Find Full Text PDFHeterogenous Tau Pathology in the Hippocampus of Progressive Supranuclear Palsy.
Alzheimers Dement
December 2024
University of Michigan, Ann Arbor, MI, USA
Background: Globose neurofibrillary tangles (NFTs) are found in subcortical areas of post‐mortem brain from individuals with the second most common primary tauopathy, progressive supranuclear palsy (PSP). The degree of cognitive impairment in secondary tauopathies such as Alzheimer’s disease (AD) correlates with the presence of NFTs, which originally appear in the entorhinal cortex before spreading throughout the hippocampus. In contrast, the degree of hippocampal tau pathology in PSP is thought to be limited, consistent with the view that cognitive impairment in PSP is predominantly subcortical.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!